ROKIT Healthcare has pulled in $41.9M (KRW 62.5B) from a group of major global private equity firms and asset managers, in a round that underscores growing international appetite for its AI-driven organ regeneration technology.

The Seoul-based company, founded in 2012, has spent over a decade building a platform that brings together artificial intelligence, 3D bioprinting, and single-use medical device kits to treat chronic conditions that conventional medicine struggles to address — among them diabetic foot ulcers, osteoarthritis, and chronic kidney disease. 

The approach is distinctly personal: rather than relying on donor tissue or synthetic materials, the platform harvests autologous fat cells directly from the patient, processes them into a custom bio-ink, and prints a regenerative patch sized to the wound — all within the operating room, in roughly 30 minutes. 

The flagship “Dr. INVIVO” platform has since earned regulatory clearance from the U.S. FDA, Korea’s Ministry of Food and Drug Safety, and European CEMDR certification, opening the door to commercialization in more than 40 countries.

About 72% of the round — $30.2M (KRW 45B) — came from overseas. Weiss Asset Management put in the largest check at $20.1M (KRW 30B), with Oasis Management contributing $4.7M (KRW 7B), Pacific Alliance Group (PAG) adding $3.4M (KRW 5B), and LMR Partners rounding out the foreign cohort at $2.0M (KRW 3B). Back home, NH Investment & Securities led a domestic tranche of $11.7M (KRW 17.5B) alongside ANDA Asset Management, GVA, and Milestone Asset Management.

ROKIT Healthcare pointed to the round’s composition — global heavyweights moving first, Korean institutions following — as a classic “global validation” signal, one that suggests the company’s science and commercial model are gaining credibility well beyond its home market.The fresh capital will go toward R&D and clinical trials across the company’s core pipeline programs. As those trials progress toward commercialization, ROKIT Healthcare expects its market cap to be reassessed accordingly. The company called the infusion of institutional “smart money” a genuine turning point in its bid to emerge as a global leader in biotech and regenerative medicine — with the institutions’ average cost basis seen as a durable support level for the stock over the long run.